Generic Korsuva Availability
Last updated on Oct 9, 2024.
Korsuva is a brand name of difelikefalin, approved by the FDA in the following formulation(s):
KORSUVA (difelikefalin acetate - solution;intravenous)
-
Manufacturer: CARA THERAP
Approval date: August 23, 2021
Strength(s): EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML) [RLD]
Has a generic version of Korsuva been approved?
No. There is currently no therapeutically equivalent version of Korsuva available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Korsuva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Synthetic peptide amides and dimers thereof
Patent 10,017,536
Issued: July 10, 2018
Inventor(s): Schteingart Claudio D. & Menzaghi Frédérique & Jiang Guangcheng & Alexander Roberta Vezza & Sueiras-Diaz Javier & Spencer Robert H. & Chalmers Derek T. & Luo Zhiyong
Assignee(s): Cara Therapeutics, Inc.The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low PCYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
Patent expiration dates:
- November 12, 2027✓✓
- November 12, 2027
-
Synthetic peptide amides
Patent 10,138,270
Issued: November 27, 2018
Inventor(s): Schteingart Claudio D. & Menzaghi Frédérique & Jiang Guangcheng & Alexander Roberta Vezza & Sueiras-Diaz Javier & Spencer Robert H. & Chalmers Derek T. & Luo Robert Zhiyong
Assignee(s): Cara Therapeutics, Inc.The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low PCYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:
Patent expiration dates:
- November 12, 2027✓
- November 12, 2027
-
Synthetic peptide amides
Patent 10,793,596
Issued: October 6, 2020
Inventor(s): Schteingart Claudio D. & Menzaghi Frédérique & Jiang Guangcheng & Alexander Roberta Vezza & Sueiras-Diaz Javier & Spencer Robert H. & Chalmers Derek T. & Luo Robert Zhiyong
Assignee(s): Cara Therapeutics, Inc.The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low PCYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:
Patent expiration dates:
- November 12, 2027✓✓✓
- November 12, 2027
-
Patent 7,402,564
Patent expiration dates:
- November 12, 2027✓✓✓
- November 12, 2027
-
Patent 7,713,937
Patent expiration dates:
- November 12, 2027✓✓✓
- November 12, 2027
-
Patent 7,727,963
Patent expiration dates:
- November 12, 2027✓✓✓
- November 12, 2027
-
Synthetic peptide amides
Patent 8,217,007
Issued: July 10, 2012
Inventor(s): Schteingart Claudio D. & Menzaghi Frédérique & Jiang Guangcheng & Alexander Roberta Vezza & Sueiras-Diaz Javier & Spencer Robert H. & Chalmers Derek T. & Luo Robert Zhiyong
Assignee(s): Cara Therapeutics, Inc.The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low PCYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:
Patent expiration dates:
- November 12, 2027✓
- November 12, 2027
-
Uses of synthetic peptide amides
Patent 8,236,766
Issued: August 7, 2012
Inventor(s): Schteingart Claudio D. & Menzaghi Frederique & Jiang Guangcheng & Alexander Roberta Vezza & Sueiras-Diaz Javier & Spencer Robert H. & Chalmers Derek T. & Luo Zhiyong
Assignee(s): Cara Therapeutics, Inc.The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low PCYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
Patent expiration dates:
- November 12, 2027✓
- November 12, 2027
-
Synthetic peptide amides and dimeric forms thereof
Patent 8,486,894
Issued: July 16, 2013
Inventor(s): Schteingart Claudio D. & Menzaghi Frédérique & Jiang Guangcheng & Alexander Roberta Vezza & Sueiras-Diaz Javier & Spencer Robert H. & Chalmers Derek T. & Luo Zhiyong
Assignee(s): Cara Therapeutics, Inc.The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low PCYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
Patent expiration dates:
- November 12, 2027✓
- November 12, 2027
-
Synthetic peptide amides and dimers thereof
Patent 8,536,131
Issued: September 17, 2013
Inventor(s): Schteingart Claudio D. & Menzaghi Frédérique & Jiang Guangcheng & Alexander Roberta Vezza & Sueiras-Diaz Javier & Spencer Robert H. & Chalmers Derek T. & Luo Zhiyong
Assignee(s): Cara Therapeutics, Inc.The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low PCYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
Patent expiration dates:
- November 12, 2027✓✓✓
- November 12, 2027
-
Synthetic peptide amides and dimers thereof
Patent 9,334,305
Issued: May 10, 2016
Inventor(s): Schteingart Claudio D. & Menzaghi Frédérique & Jiang Guangcheng & Alexander Roberta Vezza & Sueiras-Diaz Javier & Spencer Robert H. & Chalmers Derek T. & Luo Zhiyong
Assignee(s): Cara Therapeutics, Inc.The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low PCYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure:
Patent expiration dates:
- November 12, 2027✓
- November 12, 2027
-
Synthetic peptide amides
Patent 9,359,399
Issued: June 7, 2016
Inventor(s): Schteingart Claudio D. & Menzaghi Frédérique & Jiang Guangcheng & Alexander Roberta Vezza & Sueiras-Diaz Javier & Spencer Robert H. & Chalmers Derek T. & Luo Robert Zhiyong
Assignee(s): Cara Therapeutics, Inc.The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low PCYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I:
Patent expiration dates:
- November 12, 2027✓
- November 12, 2027
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 23, 2026 - NEW CHEMICAL ENTITY
More about Korsuva (difelikefalin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: peripheral opioid receptor agonists
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.